OMedLive

CME Presentations

Multiple Myeloma


Presentations

  • CME
    1.0

    Emerging Therapies for Relapsed/Refractory Multiple Myeloma

    Speakers:Ravi Vij, MD, MBA, Professor of Medicine, Section of BMT and Leukemia, Division of Medical Oncology
    David Dingli, MD, PhD, Professor of Medicine, Hematology

    Duration: 60 minutes

    Presented on: September 13, 2017


Speakers

  • Ravi Vij, MD, MBA

    Ravi Vij, MD, MBA

    Ravi Vij, MD, MBA

    Professor of Medicine, Section of BMT and Leukemia, Division of Medical Oncology

    Ravi Vij, MD, MBA, is professor of medicine in the Division of Medical Oncology, Section of Bone Marrow Transplantation and Leukemia at Washington University School of Medicine in Saint Louis, Missouri. Dr Vij’s primary academic interests include the treatment of hematologic malignancies and hematopoietic stem cell transplantation, and his research interests involve multiple myeloma and acute myeloid leukemia (AML)/myelodysplastic syndromes. He serves on numerous committees, is an author or coauthor of over 150 publications in journals, is the author of the book, Contemporary Management of Multiple Myeloma, and has served as a reviewer for publications that include Blood, Journal of Clinical Oncology, and Leukemia and Lymphoma. He received his MD from the University of Delhi, India.
  • David Dingli, MD, PhD

    David Dingli, MD, PhD

    David Dingli, MD, PhD

    Professor of Medicine, Hematology

    David Dingli, MD, PhD, is a professor of medicine within the Division of Hematology, Department of Internal Medicine, at Mayo Clinic in Rochester, Minnesota. Dr Dingli’s clinical practice is dedicated to the care of patients with multiple myeloma and related disorders. His research aims to develop and optimize the use of replicating viruses for cancer therapy, with focus areas in mathematical models and clonal evolution in hematopoiesis. He has published over 200 articles and more than 200 abstracts, mostly related to multiple myeloma and its therapy. Dr Dingli earned his medical degree from the University of Malta Medical School in Guardamangia, Malta.

CME Information

Emerging Therapies for Relapsed/Refractory Multiple Myeloma

 

Provided by the University of Nebraska Medical Center, Center for Continuing Education

ACKNOWLEDGEMENT This activity is supported by an educational grant from AbbVie, Karyopharm Therapeutics Inc., and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

TUITION Complimentary

ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education. The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS Live Activity The University of Nebraska Medical Center, Center for Continuing Education designates the live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hour of credit for completing this program.

DATE OF RELEASE/EXPIRATION Live Activity Wednesday, September 13, 2017 from 1:00 PM EST – 2:00 PM EST Enduring Material The enduring material will be available from September 13, 2017 – March 13, 2018.

ACTIVITY DESCRIPTION The prospects for patients diagnosed with multiple myeloma (MM) have improved dramatically in the past decade, with median survival increasing from as little as 3 years up to 8 years with improvements in therapy. Unfortunately, patients relapse or become refractory to treatment with time. New and emerging therapies are changing the treatment landscape and providing better outcomes for those with relapsed/refractory MM, but only if clinicians are knowledgeable and competent of their use. Newly approved and emerging targeted therapies require a more nuanced understanding of their efficacy and safety profiles than older chemotherapeutic agents, particularly for agents to be used in combination with proteasome inhibitors, immunomodulatory agents, and dexamethasone. Cytogenetic factors, disease-related factors such as depth and duration of remission and aggressiveness and rapidity of relapse, and patient-related factors such as age, performance score, and comorbidities, and must all be considered in treatment planning. With numerous agents under investigation, busy health care professionals are challenged to stay abreast of this field. This activity aims to discuss the role of new and emerging therapies in MM, particularly for patients with relapsed/refractory MM, and their therapeutic implications in combination with currently available treatment options.

LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:

Identify disease–related, patient-related, and cytogenetic factors that shape treatment decisions for the management of relapsed/refractory MM
Examine safety and efficacy data of emerging strategies for patients with MM who have received prior lines of therapies including proteasome inhibitors and immunomodulatory agents
Adopt evidence-based best practices in managing carcinoid syndrome, including strategies to address refractory or poorly controlled symptoms
Discuss the therapeutic implications of combination regimens involving emerging agents with currently available treatment option
 

INTENDED AUDIENCE This activity is intended for US-based hematologist-oncologists, oncologists, oncology nurses, internal medicine physicians, family medicine/primary care physicians, and other clinicians who care for patients with multiple myeloma.

ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to http://www.omedlive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FINANCIAL DISCLOSURES

Presenters Disclosures
David Dingli, MD, PhD

Research Funding: Karyopharm Therapeutics Consulting/Member of IRC: Millennium/Takeda Consulting: Janssen; Alexion Pharmaceuticals

Raji Vij, MD, MBA

Research Grant: Amgen; Takeda Advisory Board/Honoraria: Amgen; Takeda; Celgene; BMS; Janssen; Karyopharm Therapeutics; AbbVie; Jazz Pharmaceuticals

 

University of Nebraska Medical Center, Center for Continuing Education  
Lois Colburn, Executive Director Has nothing to disclose.
Brenda C. Ram, CMP, CHCP, Coordinator Has nothing to disclose.
PlatformQ Health Education, LLC  
Anne Roc, PhD, Medical Director Has nothing to disclose.
Karen Greb-Murphy, Program Manager Has nothing to disclose.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable): The University of Nebraska Medical Center, Center for Continuing Education requires the presenter(s) to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.

DISCLAIMERS (if applicable): The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material. The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Nebraska Medical Center, Center for Continuing Education, OMedLive, PlatformQ Health or the program grantors. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

CONTACT INFORMATION Accreditation Support: Please contact the University of Nebraska Medical Center, Center for Continuing Education at conted@unmc.edu or call 402-559-4152. Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.